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The genome of a cancer cell carries somatic muta-
tions that are the cumulative consequences of the
DNA damage and repair processes operative during
the cellular lineage between the fertilized egg and the
cancer cell. Remarkably, thesemutational processes
are poorly characterized. Global sequencing initia-
tives are yielding catalogs of somatic mutations
from thousands of cancers, thus providing the
unique opportunity to decipher the signatures of
mutational processes operative in human cancer.
However, until now there have been no theoretical
models describing the signatures of mutational pro-
cesses operative in cancer genomes and no system-
atic computational approaches are available to deci-
pher these mutational signatures. Here, by modeling
mutational processes as a blind source separation
problem, we introduce a computational framework
that effectively addresses these questions. Our
approach provides a basis for characterizing muta-
tional signatures from cancer-derived somatic muta-
tional catalogs, paving the way to insights into the
pathogenetic mechanism underlying all cancers.
INTRODUCTION
All cancer genomes carry somatic mutations. A small minority
are ‘‘drivers’’ of oncogenesis that confer selective clonal growth
advantage. The remainder are ‘‘passengers’’ that have not been
positively selected during the evolution of the neoplasm (Stratton
et al., 2009). Global sequencing projects are generating catalogs
of somatic mutations from tens of thousands of cancers (Hudson
et al., 2010). The mutations within these catalogs are the cumu-
lative result of all the somatic mutational mechanisms, including
DNA damage and repair processes, that have been operative
during the cellular lineage starting from the fertilized egg
from which the cancer patient developed to the cancer cell
(Stratton, 2011). Because the large majority of mutations in
cancer genomes are believed to be passengers, their patterns
are largely unmodified by selection (Rubin and Green, 2009).
Thus, the mutational catalog from a cancer cell may be treated246 Cell Reports 3, 246–259, January 31, 2013 ª2013 The Authorsas a representative archaeological record bearing the combined
imprints or signatures of the mutational processes that have
been operative.
Several mutational processes are already known to leave
characteristic mutational signatures in the mutational catalogs
of cancer cells. For example, analyses of mutated cancer genes
in tumors of the lung and skin have shown that the classes
of mutations found match those induced experimentally by
tobacco carcinogens and ultraviolet light respectively, the major
known exogenous carcinogenic influences in these cancer types
(Hainaut and Pfeifer, 2001; Pfeifer et al., 2002, 2005). Notably,
C:G > A:T transversions predominate in smoking-associated
lung cancer, whereas C:G > T:A transitions occurring mainly at
dipyrimidines and CC:GG > TT:AA double nucleotide substitu-
tions are common in UV light-associated skin cancers. Thus,
strong exposures to exogenous mutagens are known to leave
their imprints as mutational patterns in cancer genomes.
In principle, other biological processes may influence the
patterns of somatic mutations found in human cancers. There
may be additional exogenous mutagenic exposures. For ex-
ample, many widely used chemotherapeutic cancer treatments
are mutagens and some have already been shown to leave
a distinctive mutational signature in the genomes of cancers
recurring after therapy (Hunter et al., 2006). Moreover, there
may be exogenous mutagenic exposures instrumental in the
primary etiology of cancer that we are currently unaware of.
Endogenous sources of mutagens may also contribute to muta-
tions in cancer. For example, intrinsic cellular processes such as
energy metabolism and lipid peroxidation are sources for reac-
tive chemicals (e.g., reactive oxygen species) that cause DNA
damage (Pluskota-Karwatka, 2008). These endogenous muta-
gens are known to generate certain subclasses of mutation
and, thus, also might shape mutational catalogs within cancer
genomes (Ames and Gold, 1991).
The cell employs repair mechanisms that protect the integrity
of the genetic code by alleviating and correcting the effects of
exogenous and endogenous mutagens (Berwick and Vineis,
2000). For example, the base excision and nucleotide excision
repair pathways act on DNA damage respectively caused by
cellular metabolites and a wide variety of helix-distorting DNA
lesions (Fuss and Cooper, 2006). These repair processes, in
turn, influence the mutational signatures left by DNA damaging
agents in the final catalog of mutations. This pertains when
the repair processes are fully operative, for example the
transcriptional strand bias observed in somemutational catalogs
that is conferred by the transcription-coupled component of
nucleotide excision repair (van Zeeland et al., 2005). It may
also apply when they are malfunctioning, for example in the
mutational signatures left by defective DNA mismatch repair
(Greenman et al., 2007).
In most human cancer types, the mutational signatures im-
printed by DNA damage and repair processes have been subject
to very limited characterization. In consequence, our under-
standing of the underlying mutational processes is poor. Previ-
ously, we reported an initial outline of a way to extract mutational
signatures from the substitutions found in 21 breast cancer
genomes (Nik-Zainal et al., 2012a). In this article, we provide
a detailed description of our theoretical model that bridges the
gap between mutational catalogs derived from cancer genomes
and the mutational signatures contained in these catalogs.
Further, we provide a systematic computational framework
that can be used for accurately deciphering signatures of muta-
tional processes from mutational catalogs of cancer genomes.
We extensively evaluate our framework with simulated and real
data, demonstrating that it allows incorporation of a wide variety
of different mutation types (e.g., substitutions, indels, strand
bias, kataegis, etc.). Our framework is freely available (see
Experimental Procedures for details) and robust to a large range
of different parameters that define its domain of applicability.
Importantly, we demonstrate the applicability of the approach
to genome and exome sequences and its potential to identify
surprising biological insights.
RESULTS
Modeling Mutational Processes Operative in Cancer
Genomes
Somatic mutations are conventionally grouped into four classes;
base substitutions, small indels, rearrangements, and copy
number changes. These can be further subclassified into biolog-
ically meaningful subgroups. For example, base substitutions
are often classified into six subtypes; C:G > A:T, C:G > G:C,
C:G > T:A, T:A > A:T, T:A > C:G, and T:A > G:C. Classification
of substitutionsmay be further refined by including the sequence
context of each mutated base, either 50 or 30 or both. For
example, a C:G > T:Amutation can be characterized as TpCpG>
TpTpG (mutated base underlined and presented as the pyrimi-
dine partner of the mutated base pair) generating 96 possible
mutation types (6 types of substitution * 4 types of 50 base * 4
types of 30 base). This can be further elaborated by considering
the transcriptional strand on which a substitution resides. In
principle, similar approaches could be taken for the other major
classes of mutation (i.e., indels, rearrangements, and copy
number changes) and all classes and subclasses of mutation
could be incorporated into one analysis.
For the purpose of mathematical modeling, a limited number
of features of a mutational signature need to be selected. The
choice of features may be influenced by prior biological knowl-
edge and is constrained by statistical considerations and the
available data. In this study, a signature of a mutational process
is represented as a discrete probability density function with
a domain of preselected mutation features. Mathematically,Cmutation features can be expressed as a finite alphabet X with
K letters (each letter corresponds to a mutation feature) and,
by definition, a mutational signature P1 is a lexicographically
ordered K-tuple; P1 = ½p11;p21;.pK1 T , where pi1 is the probability
of process P1 to cause the mutation feature corresponding to
the i-th letter of the alphabet X, and because pi are probabilities:
XK
k = 1
pk1 = 1 and p
k
1R0; k = 1.K: (Equation 1)
Different cancer genomes can be exposed to a particular
mutational process at different intensities. For example, a muta-
tional process could cause 1,000 mutations in one cancer
genome while causing 20,000 in another. Hence, a mutational
process with signature P1 has an exposure (i.e., number of
mutations caused), e1g, in a cancer genome g. Note that the
subscript of a signature P1 matches the superscript of the expo-
sure e1g thus denoting that the exposure e
1
g associates with
signature P1.
The mutational catalog of a cancer genome, defined over an
alphabet of mutation types X, can be mathematically expressed
as,mg, a mapping from a genome g and finite alphabet of muta-
tion types X to a specific nonnegative K-tuple. Further, a cancer
somatic mutation catalog can be examined as a linear superpo-
sition of the signatures and intensities of exposure of mutational
processes active at some point in the lineage of cells leading
to the cancer cell, plus added noise due to nonsystematic
sequencing or analysis errors. Systematic sequencing and
analysis errors will be considered as ‘‘synthetic mutational
processes’’ with specific profiles present in some (or all)
genomes.
An example of three mutational processes with signatures
Pj = ½p1j ;p2j ;.p6j T , where j = 1.3, composing the muta-
tional catalog of a single cancer genome, g = 1, i.e.,
mg = ½m11;m21;.m61T , is shown in Figure 1A. Each of the signa-
tures has a specific distribution over the six base substitutions.
The first signature has a substantial proportion of C:G > T:A
mutations and contributes, in total, 1,000 mutations to the
cancer genome. The second process has a high proportion of
C:G > A:T mutations while contributing 1,500 mutations. The
third process generates substantial numbers of T:A > C:G muta-
tions and contributes 750 mutations (Figure 1A). The mutational
catalog of the cancer genome formed by these three processes,
however, does not have any notable or specific features and
does not obviously resemble any of the mutational signatures
that generated it. It contains, in total, 3,315 mutations, 3,250
(98%) contributed by the three mutational processes and the
remaining 65 (2%) by white noise corresponding to minor
processes or experimental errors in generating the mutation
catalog of the genome.
Mathematically, we can express mutational signatures as
a matrix (Experimental Procedures), and thus the i-th mutation
type mig of the catalog of a cancer genome g can be approxi-
mately expressed as the sum of the i-th mutation type of all oper-
ative processes and their exposures (ignoring the noise term):
migz
XN
n= 1
pine
n
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Figure 1. Modeling Signatures of Mutational Processes Operative in Cancer Genomes
(A) Simulated example of three mutational processes operative in a single cancer genome. The mutational catalog of the cancer genome is modeled as a linear
superposition of the signatures of the three processes and the respective number of mutations contributed by each signature, plus added nonsystematic noise.
(B) Simulated example illustratingmutational processes operative in a set ofG cancer genomes. Themutational catalogs of theseG cancer genomes can be used
to decipher the signatures ofNmutational processes as well as the number of mutations caused by each of the processes in each of the genomes. The extracted
signatures and contributions do not allow an exact reconstruction of the original set, thus resulting in genome-specific reconstruction error.We can generalize Equation 2 for all K mutation types and
G genomes by expressing exposures to mutational pro-
cesses and mutational catalogs as matrices (Experimental
Procedures):
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MzP3E: (Equation 3)
Deciphering the Signatures of Mutational Processes
from Somatic Mutational Catalogs of Cancer Genomes
The signatures of N different mutational processes and their
respective exposures need to be extracted from a set of muta-
tional catalogs M that contain G cancer genomes (Figure 1B).
This is equivalent to finding P and E in Equation 3 while only
knowing M. The problem can be considered as a specific case
of the classic ‘‘cocktail party’’ problem, where multiple people
attending a party are speaking simultaneously while several
microphones placed at different locations are recording the
conversations. Each microphone captures a mixture of all
sounds and the problem is how to decipher the individual
conversations from the recordings. This becomes possible
because each microphone captures each conversation with
a different intensity depending on the distance between the
microphone and the conversation. Analogously, provision of
a catalog of somatic mutations from a cancer genome provides
only the final mixture of the signatures of all mutational
processes operative in a cancer sample, and the goal is to deci-
pher these signatures froma set of availablemixtures (Figure 1B).
Thus, the mutational processes and their signatures are the
‘‘conversations,’’ the exposure to a process is the ‘‘loudness of
the conversation,’’ the cancers themselves are the ‘‘micro-
phones,’’ and the final mutational catalogs are the ‘‘recordings.’’
The cocktail party problem is a type of blind source separa-
tion (BSS) problem that involves unscrambling latent (not
observed) signals from a set of mixtures of these signals,
without knowing anything about the mixing. A number of
approaches have been previously developed for solving BSS
problems (Comon, 2010) by making specific assumptions about
the original sources. The intrinsic nonnegative nature of our BSS
cancer genomics problem (see Equation 3) requires a method
that assumes (at the very least) nonnegativity of the original
sources. One such established approach that has previously
been shown to extract biologically meaningful components
from complex biological data is nonnegative matrix factorization
(NMF) (Lee and Seung, 1999). In this study, we use NMF to solve
our BSS cancer genomics problem and decipher signatures
of mutational processes from mutational catalogs of cancer
genomes.
ExtractingMutational Signatures fromCancer Genomes
An example of applying our theoretical approach to a set of 100
simulated cancer genome mutational catalogs is shown in Fig-
ure 2. Similar to many human cancer genomes (Greenman
et al., 2007; Nik-Zainal et al., 2012a; Stratton, 2011; Wood
et al., 2007), every simulated genome contains between 500
and 50,000 substitutions. The simulated mutations were gener-
ated using ten mutational processes with distinct signatures
each with 96 mutation types (equivalent to the six substitu-
tion types and their immediate 50 and 30 sequence context).
Poisson noise was added to all simulated data (Experimental
Procedures).
Identifying the number, N, of mutational processes operative
in a set of cancer genomes is required prior to deciphering their
signatures. Our model selection approach identifies N by
applying the method for different values of N (Experimental
Procedures). For every N, we then evaluate the similarity
between the extracted processes (i.e., process reproducibility)
from stochastically initialized iterations. Further, for every N,
our model selection approach assesses the average Frobenius
reconstruction error of the averaged deciphered signatures P
and their strengths E, i.e., kM P3Ek2F . Low reconstruction
error is indicative of an accurate description of the original
cancer genome catalogs. We select the value of N for which
the extracted processes are reproducible and the reconstruction
error is low. Overfitting is avoided by bootstrapping the dataC(in each iteration) before applying NMF to it (for details see
Experimental Procedures).
For the 100 simulated cancer genomes, we are able to identify
reproducible solutions for N between two and ten (Figure 2A).
Increasing the number of signatures from two to ten substantially
reduces the reconstruction error, but increasing beyond ten
does not further reduce it (Figure 2A). This indicates that our
approach can ‘‘optimally’’ distinguish the signatures of tenmuta-
tional processes, precisely the number originally used to simu-
late the mutational catalogs of the 100 cancer genomes. The
ten deciphered signatures are very reproducible (average silhou-
ette width >0.96, Experimental Procedures) as well as extremely
similar (average cosine similarity >0.98, see below) to the ones
used to generate the 100 mutational catalogs (Figure 2B).
Further, our approach was able to accurately identify the number
of mutations contributed by each of the ten processes in each of
the genomes. Comparison between original and deciphered
contributions of one of the signatures in all genomes is shown
in Figure 2C whereas a comparison of the contributions of all
10 signatures in a single genome is shown in Figure 2D. A typical
comparison between an original and deciphered signature is
shown in Figure 2E, whereas a typical comparison between an
original and reconstructed mutational catalog of a genome is
depicted in Figure 2F.
Identification of Factors that Influence Extraction
of Mutational Signatures
To identify factors that affect the ability to extract mutational
signatures, we simulated mutational processes under a number
of scenarios and compared the deciphered signatures to those
used to simulate the data (Experimental Procedures).
To evaluate how the degree of similarity between mutational
signatures affects their extraction, we simulated sets of four
randomly generated signatures; two were very different from
any of the other signatures, whereas the similarity of the remain-
ing two to each other was varied (Figure S1A). A cosine correla-
tion similarity was used as a measure of closeness. This ranges
between zero and one, where a similarity of one represents iden-
tical signatures and a similarity of zero completely different
mutational signatures (Experimental Procedures). Our simula-
tions indicate that 50 or more cancer genomes allow accurate
deciphering of signatures that are extremely similar (Figure 3A).
Interestingly, however, as few as 20 genomes are adequate to
effectively extract signatures that have reasonable similarities
between them (Figure 3B).
The number of available genomes mathematically limits the
number of signatures that can be extracted. For example, accu-
rately deconvoluting signatures of 15 mutational processes
from the mutational catalogs of only ten cancer genomes is in-
effective. Simulations with different numbers of genomes and
mutational signatures demonstrate that the number of cancer
catalogs required for accurately deciphering the signatures
operative in them increases exponentially with the number of
signatures (Figures 3C and S1B). Thus, although mutational
catalogs from 100 cancer genomes are needed to extract the
signatures of 15 mutational processes, at least 200 cancer
genome catalogs are required for deconvoluting 20 signatures
(Figure 3C). Nevertheless, it is possible to decipher at leastell Reports 3, 246–259, January 31, 2013 ª2013 The Authors 249
Figure 2. Deciphering Signatures of Mutational Processes from a Set of Simulated Mutational Catalogs from 100 Cancer Genomes
(A) Identifying the number of processes operative in a set of 100 simulated cancer genomes based on reproducibility of their signatures and low error for re-
constructing the original catalogs.
(B) Comparison between the ten deciphered signatures and the ten signatures used to simulate the catalogs. Signature recognition, measured using cosine
similarity, and signature reproducibility, measured using average silhouette width, is given for each mutational signature. The error bars represent the SD of the
corresponding characteristics for the extracted signature(s).
(C) Comparison between deciphered and simulated contributions of one of the ten mutational processes in all cancer genomes.
(D) Comparison between deciphered and simulated contributions of all signatures in a typical cancer genome. The error bars represent the SD of the corre-
sponding characteristics for the extracted signature(s).
(E) Comparison between the profiles of typical deciphered and simulated signature. The error bars represent the SD of the corresponding characteristics for the
extracted signature(s).
(F) Comparison between themutational catalogs of a typical deciphered (red line) and simulated (dark blue line) cancer genome. The separately bootstrapped per
iteration mutational catalogs (Experimental Procedures), which are used to decipher the mutational signatures and their contributions, are shown in light blue.some of the 20 mutational signatures from a set of 100 or fewer
mutational catalogs (Figure S1C).
The number of mutations in each cancer catalog affects the
ability to decipher signatures of mutational processes. Simu-
lating the mutational catalogs of 50 cancer genomes with
different average numbers of mutations indicates that two or250 Cell Reports 3, 246–259, January 31, 2013 ª2013 The Authorsthree signatures can be effectively extracted from catalogs
with very few mutations, whereas extracting seven or more
signatures requires an average of at least 1,000 mutations per
catalog (Figure 3D). Interestingly, at least 500 mutational cata-
logs with an average of 96 mutations per catalog (a total of
50,000 mutations) are needed to decipher five mutational
processes (Figure 3E), but these five mutational processes can
be more easily deciphered from 50 cancer genomes containing
an average of 480 mutations (a total of 25,000 mutations, Fig-
ure 3D). This result indicates that it is more effective to decipher
mutational signatures from a few catalogs containing many
mutations than from many catalogs containing few mutations
(most likely due to the high relative Poisson variance for small
number of mutations).
The strength of exposure of a mutational process in a set
of genomes also influences the ability to decipher its signature.
Simulations of seven signatures operating with different
strengths in 50 mutational catalogs (i.e., exposure to Signature
I is fixed whereas the remaining six signatures account for the
rest of the mutations) reveal that signatures contributing <5%
of all mutations can be difficult to distinguish (Figure 3F). Simi-
larly, deciphering members of a set of mutational signatures
that have similar exposures with respect to each other over
a set of cancer genomes is also challenging (Figure 3F). To over-
come this problem, it may be advantageous to combine sets of
mutational catalogs in which mutational processes are more
likely to be active in different proportions (e.g., from different
cancer types). However, combining sets of mutational catalogs
in this way should be considered with caution as the number of
cancer genomes required for extraction of signatures increases
exponentially with the number of operative signatures and
more cancer types may well entail more signatures (Figures 3C
and S1B).
In addition to decipheringmutational signatures, our approach
extracts the number of mutations contributed by each signature
to each cancer genome. Evaluating the average deciphering
error for identifying contributions reveals that accurately deci-
phered mutational signatures (i.e., cosine similarity between
simulated and extracted signatures >0.95) are associated with
low error for their respective signature contributions (Figures
3F and S1D). Further, the contributions of signatures generating
large numbers of mutations (>200) are generally associated with
lower error rates (Figure S1E).
Deciphering the Signatures of Mutational Processes
Operative in the Genomes of Breast Cancers
We recently described five mutational signatures derived from
the 96 possible mutated trinucleotides within the mutational
catalogs of 21 whole breast cancer genomes, named Signatures
A–E (Nik-Zainal et al., 2012a). Signature A is likely due to deam-
ination of 5-methylcytosine, a relatively well-characterizedmuta-
tional process. The processes underlying the other signatures
are not known, but we have suggested that members of the
APOBEC family of DNA/RNA editing enzymes may be respon-
sible for some. Other mutational signatures were detected by
visual inspection, including double nucleotide substitutions,
a localized base substitution hypermutation phenomenon
dubbed kataegis and different patterns of indels occurring either
at short tandem repeats or with overlapping microhomologies at
breakpoints.
We applied our framework (Experimental Procedures) to the
21 mutational catalogs. This extracted four reproducible muta-
tional Signatures 1–4 (Figure 4A), similar respectively to the
previously reported Signatures A, B, D, and E (Nik-Zainal et al.,C2012a). However, our new model selection approach and boot-
strapping render 21 genomes inadequate to identify the fifth
signature with sufficient accuracy. The previously reported
mutational Signature C, which is missing from this analysis is
quite similar to Signature D, and appears predominantly to
have been incorporated here into Signature 3 (Figure 4A). This
illustrates the overall reproducibility of the results together with
some vulnerability to underlying methodological changes, par-
ticularly when the number of genomes is limited and mutational
processes are similar to each other.
In principle, our framework can be applied to awider repertoire
of mutation types than the 96 mutated trinucleotides. To demon-
strate the potential of this approach, we extended the range
of mutation features to include kataegis and double nucleotide
substitutions as well as indels at microhomologies and at
mono/polynucleotide repeats. Thus, four additional mutational
subclasses were incorporated in this model.
Applying this model selection approach revealed five muta-
tional signatures. The substitution patterns of Signatures 1–4
were largely unmodified (Figures 4A and S2). The fifth signature
was characterized primarily by kataegis, indicating that kataegis
is mostly independent from the other four mutational signatures
(Figure 4B). Indels did not have a strong association with Signa-
tures 2 and 5; Signatures 3 and 4 were predominantly associ-
ated with indels at microhomologies, whereas Signature 1
associated with nucleotide repeat-based indels (Figure 4C).
Double nucleotide substitutions associated mainly with Signa-
ture 3 and weakly with the other four signatures. These analyses
illustrate the possibility of incorporating additional mutation
types and reveal some preliminary associations (and nonassoci-
ations) with the previously defined Signatures. However, the
numbers of dinucleotides and indels is relatively small and it is
therefore unclear if these two mutation classes will keep their
current Signature associations or segregate into independent
mutational signatures when many more cancer genomes are
analyzed.
Our previous analyses showed a transcriptional strand bias for
all C:G > A:T mutations across the 21 breast cancer mutational
catalogs (Nik-Zainal et al., 2012a). This bias resulted in C > A
mutations being more common on the transcribed than the
untranscribed strands of genes (and vice versa for G > T). We
do not know the cause of this strand bias, but it could be due
to past activity of transcription-coupled nucleotide excision
repair. We investigated whether a particular mutational signature
was associated with the transcriptional strand bias by including
information on whether a substitution mutation was on the tran-
scribed or nontranscribed strand, thus increasing the 96 trinucle-
otide substitutions to 192. Our model selection approach again
revealed the signature of four reproducible mutational processes
(Figure 5A). The C > A strand bias was not observed in Signa-
tures 2 and 4, but associated with Signature 1 and, to a lesser
extent, Signature 3.
Our previous assessment of the impact of sequence context
on classification of mutational processes was limited to the
bases immediately 50 and 30 to each mutated base. However,
other sequence motifs close to or distant from the mutant
base could be important in defining a mutational process.
Here, we have extended the sequence context to include theell Reports 3, 246–259, January 31, 2013 ª2013 The Authors 251
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two bases 50 and 30 to each mutated base, which results in
1,536 possible mutated pentanucleotides. For example, one
of the 256 subclasses of C:G > T:A mutation would be
.ApTpCpGpC. > .ApTpTpGpC. (mutated base under-
lined). Our model selection approach is able to find three repro-
ducible mutational processes with these 1,536 mutation types.
Analyzing more mutation types leads to fewer mutations per
mutation type, thus increasing the relative variability in the
bootstrapping procedure (Experimental Procedures), which
diminishes the ability of our approach to find the signatures
of the operative mutational processes. This limitation should
be taken in consideration when choosing the number of muta-
tion types that are being analyzed. Despite this limitation, we
can observe new sequence context dependencies in at least
one of these processes (Figure 6A). Signature 2 substitutions
at TpCpN trinucleotides are dependent on the next base 50,
which is predominantly a pyrimidine (Figures 6A and 6B). Of
all C > X at TpCpN mutations caused by Signature 2, 41%
are at CpTpCpN, 33% at TpTpCpN, and the remaining 26%
are either G or A 50 to the TpCpN trinucleotide (Figure 6C).
Such a tetranucleotide distribution is highly unlikely to happen
purely by chance in the human genome (c2 test, p value <
0.0001). The result illustrates the richness of detail potentially
revealed by this type of analysis, which may be of value in
future comparisons of signatures extracted from different
cancer types or experimental systems.
Using Mutational Catalogs from Exome Sequencing
to Deconvolute Mutational Signatures
The combined protein coding exons (the ‘‘exome’’) constitute
1% of the human genome. Analysis of exomes compared to
whole genome sequences is often perceived as advantageous
because of lower cost and because a substantial proportion of
cancer-causing driver somatic substitutions, indels, and copy
number changes (although not usually rearrangements) may be
found using this strategy. As a result, many more exome
sequences of cancers are currently being generated than whole
genomes.Figure 3. Evaluating Factors Affecting the Efficacy of Deciphering Mut
(A) Evaluating the effect of deciphering similar mutational signatures frommutatio
IV were simulated with cosine similarity between 0.9 and 1.0 (i.e., with extremely
any of the other signatures (Figure S1A).
(B) Evaluating the effect of deciphering mutational signatures with different simil
(C) Evaluating the effect of deciphering different number of mutational signatures
cancer genomes.
(D) Evaluating the effect of deciphering different number of mutational signatures f
were simulated with different average number of mutations in a cancer genome.
(E) Evaluating the effect of deciphering two, three, five, or seven mutational signat
mutations per cancer genome. The line colors correspond to the ones in (D) lege
(F) Evaluating the effect of deciphering mutational signatures with different contri
fixed to contribute a fixed percentage of all mutations in either the whole set of mu
have different contributions of Signature I (blue bars) or in each individual cance
catalog (red bars).
(G) Comparison, across all performed simulations, between the accuracy for d
contributions of these signatures. The deciphering Frobenius reconstruction erro
the number of mutations in the respective mutational catalog. In all panels, dec
sponds to extracting exactly the same process used to simulate the data.
The error bars represent the SD of the deciphering accuracies after performing e
See also Figure S1.
CWe therefore assessed the power of our approach to extract
mutational processes from exome sequences using 100 recently
sequenced breast cancer exomes (Stephens et al., 2012) con-
taining7,000 somatic substitutions, 25-fold fewer than found
in the 21 whole cancer genomes. Our framework revealed two
reproducible mutational signatures with strong similarities to
the previously described Signatures 1 and 2 (Figure 7). Thus,
mutational catalogs from exomes can be used to extract muta-
tional signatures, although not with the precision and compre-
hensiveness provided by the much larger mutation numbers in
whole genomes. It is quite possible, however, that increasing
the number of exome sequences to a few thousand will allow
identification of many mutational processes operative in breast
cancer.
Analysis of smaller, exome-derived mutational catalogs (or
catalogs from other subcomponents of the genome) may also
be useful in detecting biologically revealing features of muta-
tional processes that are particular to coding, transcribed, non-
transcribed, or other functionally distinct regions. For example,
incorporating transcriptional strand in the analysis of the 100
breast cancer exomes revealed the presence of a context-
specific (i.e., TpCpT) strand bias for Signature 2 (Figures 7B
and 7C). However, this strand bias is not observed in the version
of Signature 2 extracted from whole cancer genome sequences,
which include complete footprints (including introns and
untranslated exons) of protein coding genes, suggesting that
the underlying mechanism generating strand bias is restricted
to exons (Figures 5 and 7). Examining only the exon compart-
ments of the whole cancer genome sequences reveals the pres-
ence of this strand bias in samples with substantial exposure to
Signature 2, supporting this conclusion. This result is biologically
surprising and the mechanism underlying this difference in
strand bias between exons and introns is currently unknown.
DISCUSSION
We have modeled the signatures of somatic mutational pro-
cesses in cancer genomes as a blind source separationational Signatures with Simulated Data
nal catalogs containing different number of cancer genomes. Signatures III and
similar shapes) whereas the remaining two signatures were very different from
arities between them from mutational catalogs of 20 cancer genomes.
from sets of mutational catalogs derived from 10, 20, 30, 50, 70, 100, and 200
rom sets of mutational catalogs derived from 50 cancer genomes. The catalogs
ures from large sets of mutational catalogs containing small number of average
nd.
butions across sets of 50 mutational catalogs. Signature I’s contributions were
tational catalogs, i.e., the overall contribution is fixed but different genomes can
r genome, i.e., Signature I’s contributions are fixed in every single mutational
eciphering mutational signatures and the deciphering error for identifying the
r was calculated and averaged for each contribution and normalized based on
iphering accuracy is shown in cosine similarity where accuracy of 1.00 corre-
ach simulation scenario 100 times.
ell Reports 3, 246–259, January 31, 2013 ª2013 The Authors 253
Figure 4. Signatures of Mutational Processes Extracted from the Mutational Catalogs of 21 Breast Cancer Genomes
(A) Four mutational signatures deciphered from the base substitutions (including their immediate 30 and 50 sequence context) identified in the 21 breast cancer
genomes.
(B) A fifth mutational signature identified when kataegis, dinucleotide substitutions, and indels at microhomologies and at mono or polynucleotide repeats are
added as mutation types.
(C) Total contributions of mutations of the five signatures for kataegis, dinucleotide substitutions, and indels in the 21 breast cancer genomes.
The error bars represent the SD of the contributions for each mutation type for the deciphered signature.
See also Figure S2.problem and introduced a computational framework that
extracts these mutational signatures from the mutational
catalogs obtained from cancer genome sequences. To identify
these signatures, the intrinsic nonnegativity of mutations
mandates employment of a method incorporating a nonnegative
constraint and our simulations demonstrate that NMF is
effective in deciphering mutational signatures from mutational
catalogs.
Incorporating additional constraints in NMF could further
improve its efficiency. For example, a strong sparsity constraint
could be applied to the exposure matrix E guaranteeing that
the mutational catalog of a cancer genome is described by
a minimum number of processes. Algorithms implementing this
and other constraints have been previously developed (Berry
et al., 2007; Gao and Church, 2005; Peharz and Pernkopf,
2012; Zheng et al., 2006) and could be applied to cancer geno-
mics data. Nevertheless, this study demonstrates that an
approach based on the simplest (i.e., without additional
constraints) NMF algorithm is sufficient to decipher signatures
of mutational processes from catalogs of mutation from cancer
genomes.254 Cell Reports 3, 246–259, January 31, 2013 ª2013 The AuthorsParameters to which solutions are sensitive include the
number of operative mutational processes, the strength of their
exposures, the degree of difference between mutational signa-
tures, the number of analyzed cancer genomes, the number of
mutations per cancer genome, and the number of mutation
types that are incorporated into the model. These factors will
determine the manner in which the method will be applied to
future data sets. Importantly, the results show that, despite rela-
tively few mutations present in each case, the approach can
be applied to exome data, extracting at least some of the
signatures.
Although diverse mutation classes can be included and
analyzed by our computational framework, the choice of these
classes will largely depend on prior biological knowledge, the
available experimental data and perhaps on cancer type. Thus
application of our approach can, if desired, be limited to single
base substitutions or be widened to include double nucleotide
substitutions, indels, geographically localized forms of mutation
such as kataegis and mutation features such as transcriptional
strand bias. Following this principle, rearrangements and copy
number changes (and potentially even epigenetic changes)
Figure 5. Strand Bias in Signatures of Mutational Processes Extracted from Genic Regions of 21 Breast Cancer Genomes
(A) Four mutational signatures deciphered from the base substitutions (including their immediate 30 and 50 sequence context) identified in genic regions of 21
breast cancer genomes.
(B) Sequence context independent summary of strand bias in the four mutational signatures extracted from the 21 breast cancer genomes.
The error bars represent the SD of the contributions for each mutation type for the deciphered signature.could be incorporated, such that a comprehensive overview of
operative mutational processes could be derived. Further, the
approach can then be used to estimate the contribution of
each mutation process to each cancer and also to time the
activity of each process (Nik-Zainal et al., 2012b).
The complexity of the mutational processes operative in
some cancers and the inherent challenges in extracting their
attendant mutational signatures should not be underestimated.
For example, the mutational catalog of a lung cancer in
a tobacco smoker will carry the signature of 60 chemicals
that bind and mutate DNA (Pleasance et al., 2010). Each of
these chemicals may have its unique mutational signature. A
group of smokers loyal to the same brand will be simul-
taneously exposed to the same combination of mutagens.
Analysis of tumors from this group of individuals therefore
may not allow the mutagens to be distinguished from one
another and our model will extract one signature that encom-
passes the combined mutational activity of all 60 chemicals.
However, as different cigarette brands may contain different
combinations and amounts of mutagens, analysis of mutational
catalogs from cancers due to different tobacco brands could
allow differentiation between the signatures of each of the
different chemicals. An ambitious aspiration of this nature
would, however, probably only be feasible with data from thou-
sands of cases, coupled to the statistical power and resolutionCprovided by whole genome mutational catalogs. It should be
noted, that even the availability of tens of thousands of cancer
genomes may not allow deciphering of the full complexity of all
mutational processes occurring in the cancer cells of a person,
who has been exposed to various mutagens and treatments
throughout his/her lifetime. Nevertheless, our approach allows
deciphering the signatures of the most prevalent processes
and as the amount of available cancer genomics data
increases, it will allow better understanding cellular processes
and mutagenesis.
In our first set of experiments using data from breast cancer
genomes, we have already extracted mutational signatures for
which the underlying biological process is not known. It is
highly likely that further cryptic mutational signatures will be ex-
tracted once thousands of cancers have been analyzed. Under-
standing the biological basis of these signatures will be the next
imperative. One major approach to achieving this will be to
extract mutational signatures from systems (e.g., human cells,
mice, yeast, bacteria) with known exposures to mutagens
and/or known or engineered changes in DNA editing and repair.
Matching of cryptic mutational signatures found in naturally
occurring cancers to signatures generated in experimental
systems will provide clues to their provenance. These
approaches, applied to mutational signatures derived from
thousands of human tumors, promise to provide substantialell Reports 3, 246–259, January 31, 2013 ª2013 The Authors 255
Figure 6. Signatures of Mutational Processes Extended to Include Additional Sequence Context
(A) Signature 2 deciphered from the base substitutions (including the two bases 50 and 30 to each mutated base resulting in 1,536 possible mutated pentanu-
cleotides) identified in 21 breast cancer genomes.
(B) Detailed view of C > T mutation types in Signature 2. Purine nucleotides located two bases 50 of the mutated base are shown in green whereas pyrimidine
nucleotides are in red.
(C) Summary of all mutation types caused by Signature 2.
The error bars represent the SD of the contributions for each mutation type for the deciphered signature.insights into the DNA damage and repair processes that
underlie somatic mutagenesis across the spectrum of human
cancer.
EXPERIMENTAL PROCEDURES
Model Definition
Mutation type is mathematically represented as a letter from a K-letter
alphabet X. Mutational signature is defined as a discrete probability density
function over the domain of mutation types in X, P : X/RK+ . Thus, a signature
of a mutational process P1 can be expressed as a nonnegative K-tuple,
P1 = ½p11;p21;.pK1 T , where
PK
k = 1p
k
1 = 1 and p
k
1 is the probability of the muta-
tional processes P1 to cause the mutation type corresponding to the k-th letter
of the alphabetX. Hence, a set ofNmutational signatures can be expressed as
a nonnegativemutational signature matrix P=
"
p11 p
1
2 / p
1
N1 p
1
N
« « 1 « «
pK1 p
K
2 / p
K
N1 p
K
N
#
with
size K 3 N, where K is the number of mutation types and N is the number of
signatures. The subscript index indicates the signature, whereas the super-
script index corresponds to the mutation type.
Exposure to amutational process P1with signatureP1 = ½p11;p21;.pK1 T is the
number of mutations, e1g˛N0, attributed to that signature in genome g. In this
notation, the product p213e
1
g is the average number of mutations of type corre-
sponding to the second letter of alphabet X caused by the mutational process
P1 in a cancer genome with number g. Hence, we can express the exposure256 Cell Reports 3, 246–259, January 31, 2013 ª2013 The Authorsof G genomes to a set of N processes as a nonnegative matrix
E =
"
e11 e
1
2 / e
1
G1 e
1
G
« « 1 « «
eN1 e
N
2 / e
N
G1 e
N
G
#
with size N3G. Here, the subscript index indi-
cates the genome whereas the superscript index corresponds to the
signature.
The mutational catalog of a cancer genome g defined over the alphabet of
mutation types X is represented by mg : X/N
K
0 . For a given genome, g = 1,
its mutational catalog can be expressed as a nonnegative K-tuple,
m1 = ½m11;m21;.mK1 T . Hence, the mutational catalogs of G cancer genomes
can be expressed as a nonnegative mutational catalogs matrix
M=
"
m11 m
1
2 / m
1
G1 m
1
G
« « 1 « «
mK1 m
K
2 / m
K
G1 m
K
G
#
of size K 3 G. In this case, the genomes
form the columns of the matrix, where K is the number of mutation types
and G is the number of genomes. The subscript index indicates the genome
whereas the superscript index corresponds to the mutation type.
In our model, the mutational catalog of a cancer genome is examined as
a linear superposition of the signatures of the mutational processes operative
in this genome and their respective exposures. This can be expressed for a set
of G genomes and N mutational signatures as M z P 3 E. The approximate
equality is due to nonsystematic errors and sampling noise.Framework for Deciphering Signatures of Mutational Processes
For a given set of mutational catalogs M that contain G cancer genomes
defined over an alphabet X with K letters corresponding to mutation types
Figure 7. Signatures of Mutational Processes Extracted from the Mutational Catalogs of 100 Breast Cancer Exomes
(A) Two mutational signatures deciphered from the base substitutions (including their immediate 30 and 50 sequence context) identified in the exomes of 100
breast cancers.
(B) Strand bias signatures deciphered from the base substitutions identified in the exomes of 100 breast cancers.
(C) Sequence context independent summary of strand bias in the two mutational signatures extracted from the 100 breast cancer exomes.
The error bars represent the SD of the contributions for each mutation type for the deciphered signature.(i.e.,M has a size K3 G), we extract Nmutational signatures defined over the
same alphabet X by applying the algorithm below:
Step 1 (Dimension Reduction)
Reduce the dimensions of the original matrix M by removing any mutation
types that together account for %1% of the mutations in all genomes, i.e.,
remove the maximum set of rows R in M for which:
X
r˛R
XG
g= 1
mrg%0:013
XK
k = 1
XG
g= 1
mkg;
and the cardinality of the set R, jRj, is maximized. The matrixM is transformed
into a new matrix _M with dimensions _K3G, where _K =K  jRj.
Step 2 (Bootstrap)
Apply Monte Carlo bootstrap resampling to the dimensionally reduced matrix
_M resulting in a new matrix M
^
, where the probability for getting a mutation of
type corresponding to the qth letter in the alphabet X in a genome g is
Prðm^qgÞ= _mqg=
PK
k = 1
_mkg whereas the total number of mutations in each genome
g remains unaffected, i.e.,
PK
k =1m
^k
g =
PK
k =1
_mkg.
Step 3 (NMF)
Apply the multiplicative update algorithm (Lee and Seung, 1999) for nonnega-
tive matrix factorization to the bootstrapped data by finding the solution
to min
P˛Mð
_K;NÞ
R+
;E˛MðN;GÞ
R+
kM^  P3Ek
2
F :
1. Initialize matrices P and E as random nonnegative matrices with
respective sizes _K3G and N3G, where N is the number of signatures.C2. Iterate until convergence, defined as 10,000 iterations without change,
or until the maximum number of 1,000,000 iterations is reached:
eNG)e
N
G
h
PTM
^i
N;G
½PTPEN;G
p
_K
N)p
_K
N
h
M
^
ET
i
_K;N
½PEET  _K;N
The notation [AB]x,y is equivalent to the (x, y)
th element of the matrix C,
where C = A 3 B.
3. Store the identified signatures P and their respective exposures E.
Although there aremany freely available and commercial implementations of
the multiplicative update algorithm (Lee and Seung, 1999), the results reported
here were deriving mostly using the implementation in Brunet et al. (2004).
Step 4 (Iterate)
Perform Steps 2 and 3 for I iterations. I is determined by evaluating the conver-
gence of the iteration-averaged signature matrix P (see below for deriving P). I
is selected in a way such that performing 2 * I iterations (i.e., doubling the iter-
ations) does not significantly change P. In most cases between 400 and 500
iterations are needed, however, sometimes solutions could be found for I %
100 whereas in rare cases more than 1,000 iterations might be required. In
general, the value of I is strongly dependent on the size and type of the initial
matrix M.ell Reports 3, 246–259, January 31, 2013 ª2013 The Authors 257
Step 5 (Cluster)
The iterations performed in Step 4 result in two sets of matrices, SP ˛M
ð _K;NÞ
R+
and SE ˛M
ð _K;NÞ
R+
, that correspond respectively to the mutational signatures
and their exposures generated over the I iterations. A partition-clustering algo-
rithmwas applied to the set of matrices SP to cluster the data intoN clusters. A
variation of k-means (Jain, 2010), where each signature forcP˛Sp is assigned
to exactly one cluster, was used to partition the data. Similarities between
mutational signatures were calculated using a cosine similarity (see below)
whereas the N centroids were calculated by averaging the signatures
belonging to each cluster. The iteration-averaged matrix P was formed
by combining the N centroid vectors ordered by their reproducibility (see
Step 6). The error bars reported for each mutation type in each signature
in P were calculated as the SD of the corresponding mutation type in each
centroid over the I iterations. Note that clustering the data in SP effectively
results in clustering SE as each signature unambiguously corresponds to
exactly one exposure, thus allowing derivation of E.
Step 6 (Evaluate)
The reproducibility of the derived average signatures P is evaluated by exam-
ining the tightness and separation of the clusters used to form the centroids in
P (see Step 5). More specifically, using cosine similarity, the average silhouette
width for each of the N clusters is calculated. An average silhouette width of
1.00 is equivalent to consistently deciphering the same mutational signature,
whereas a low silhouette width indicates lack of reproducibility of the solution.
The average silhouette width (Rousseeuw, 1987) of the N clusters is used as
a measure of reproducibility for the whole solution. In addition to reproduc-
ibility, the average Frobenius reconstruction error is used to evaluate the accu-
racy with which the deciphered mutational signatures and their respective
exposures describe the original matrixM, i.e., kM P3Ek2F , where lower Fro-
benius reconstruction error corresponds to better describing the original
matrix. There is some association between the reproducibility of a solution
and its reconstruction error. For example, solutions with very low reproduc-
ibility may have iteration inconsistent high Frobenius reconstruction errors.
Last, comparison between two mutational signatures A and B, each defined
for K mutation types, is done using cosine similarity:
simðA;BÞ=
PK
k = 1
AkBkﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPK
k = 1
ðAkÞ2
s ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPK
k =1
ðBkÞ2
s :
Because the elements of A and B are nonnegative, the cosine similarity has
a range between 0 and 1. When the cosine similarity is 1 between two signa-
tures, these signatures are exactly the same. In contrast, when the similarity is
0, the signatures are independent.
Model Selection Approach
Our framework for deciphering signatures of mutational processes relies on
two input parameters, the original matrix M (size K 3 G) and the number of
mutational signatures N to be deciphered from M. However, in most cases,
the value of N is unknown and needs to be determined from M. The model
selection framework relies on applying the framework for deciphering signa-
tures of mutational processes for values of N between 1 and min(K,G)  1.
The reproducibility and average Frobenius reconstruction error are evaluated
for each N. The value of N is selected when decomposing the matrix M
results in highly reproduciblemutational signatures and low overall reconstruc-
tion error.
Simulating Mutational Catalogs of Cancer Genomes
Signatures of mutational processes with different exposures were randomly
generated and used to simulate mutational catalogs of cancer genomes.
The simulated mutational catalogs were leveraged to assess the ability of
our approach to decipher the mutational signatures with which the data
were simulated. In most cases (i.e., unless specified otherwise in the main
text), the signatures of mutational processes were stochastically generated
with similarities between them similar to those previously observed between
signatures of mutational processes derived from the mutational catalogs of
breast cancer genomes (Nik-Zainal et al., 2012a). Similarly, unless specified258 Cell Reports 3, 246–259, January 31, 2013 ª2013 The Authorsotherwise, the contributions of mutational processes were uniformly distrib-
uted across the set of simulated cancer genomes whereas the total number
of mutations in each mutational catalog was drawn from a distribution compa-
rable to the distribution of the total substitutions found in many human cancer
genomes (Greenman et al., 2007; Nik-Zainal et al., 2012a; Stratton, 2011;
Wood et al., 2007). For every mutational process with signature
P1 = ½p11;p21;.pK1 T contributing e1g mutations in a cancer genome g, each
mutation is assigned to one of the K mutation types according to the discrete
probability density function of P1. Poisson noise was added to every simulated
mutational catalog. Lastly, each simulation scenario was repeated 100 times
and the SD of the results over these 100 repeats are reported as error bars
in the respective figures.
Examined Mutation Types
Mutational catalogs were derived for each of the analyzed samples from the
previously identified substitution and indels for the 21 breast cancer whole-
genomes (Nik-Zainal et al., 2012a) and 100 breast cancer whole-exomes
(Stephens et al., 2012). The immediate 50 and 30 sequence context was ex-
tracted using the ENSEMBL Core APIs for human genome build GRCh37.
Dinucleotide substitutions were identified when two substitutions were
present in consecutive bases on the same chromosome (sequence context
was ignored). The immediate 50 and 30 sequence content of all indels was
examined and the ones present at mono/polynucleotide repeats or microho-
mologies were included in the analyzed mutational catalogs as their respec-
tive types. Kataegis substitutions were identified based on their intermutation
distances (regardless of sequence context) and excluded from the other
substitutions. Strand bias catalogs were derived for each sample using only
substitutions identified in the transcribed regions of well-annotated protein
coding genes.
Source Code
The framework for deciphering signatures of mutational processes—including
its source code, brief documentation, mutational catalogs of the 21 breast
cancer whole-genomes, mutational catalogs of 100 breast cancer whole-
exomes, and examples (that reproduce results presented in this article) of
applying it to these mutational catalogs—are freely available for download
from http://www.mathworks.com/matlabcentral/fileexchange/38724.
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